Botanix Pharmaceuticals Ltd
ASX:BOT

Watchlist Manager
Botanix Pharmaceuticals Ltd Logo
Botanix Pharmaceuticals Ltd
ASX:BOT
Watchlist
Price: 0.11 AUD Market Closed
Market Cap: 216.8m AUD

Botanix Pharmaceuticals Ltd
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Botanix Pharmaceuticals Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Botanix Pharmaceuticals Ltd
ASX:BOT
Net Income (Common)
-AU$86.4m
CAGR 3-Years
-87%
CAGR 5-Years
-39%
CAGR 10-Years
-56%
Recce Pharmaceuticals Ltd
ASX:RCE
Net Income (Common)
-AU$21.4m
CAGR 3-Years
-25%
CAGR 5-Years
-38%
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Net Income (Common)
-AU$93.8m
CAGR 3-Years
31%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Net Income (Common)
AU$149.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Clarity Pharmaceuticals Ltd
ASX:CU6
Net Income (Common)
-AU$64.3m
CAGR 3-Years
-39%
CAGR 5-Years
-56%
CAGR 10-Years
N/A
Nyrada Inc
ASX:NYR
Net Income (Common)
-AU$4.8m
CAGR 3-Years
-7%
CAGR 5-Years
3%
CAGR 10-Years
N/A
No Stocks Found

Botanix Pharmaceuticals Ltd
Glance View

Market Cap
215.7m AUD
Industry
Pharmaceuticals

Botanix Pharmaceuticals Ltd. engages in the development of therapeutics for the treatment of skin diseases. The company is headquartered in Perth, Western Australia. The firm's product pipelines are based on drug delivery technology known as Permetrex. Its product pipeline consists of three clinical programs, which are using synthetic cannabidiol in the topical treatment of serious skin diseases and for antimicrobial applications. Its product pipeline includes BTX 1503 Gel, BTX 1702 Solution and BTX 1801 Ointment. Its BTX1503 Gel is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX 1702 Solution is used for the treatment of papulopustular rosacea. Its BTX 1801 Ointment is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA). The firm also has a chemistry program to identify, synthesize and test chemical entities that are related to naturally occurring cannabinoids.

BOT Intrinsic Value
HIDDEN
Show

See Also

What is Botanix Pharmaceuticals Ltd's Net Income (Common)?
Net Income (Common)
-86.4m AUD

Based on the financial report for Jun 30, 2025, Botanix Pharmaceuticals Ltd's Net Income (Common) amounts to -86.4m AUD.

What is Botanix Pharmaceuticals Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-56%

Over the last year, the Net Income (Common) growth was -523%. The average annual Net Income (Common) growth rates for Botanix Pharmaceuticals Ltd have been -87% over the past three years , -39% over the past five years , and -56% over the past ten years .

Back to Top